Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Withdrawn 1Suspended 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 3

Sponsor

Conditions

Cancer Pain 3Pain, Intractable 2Pain 2

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × resiniferatoxin × Clear all
NCT05067257 2024-03-18

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Sorrento Therapeutics, Inc.

Phase 2 Suspended
120 enrolled

Cancer Pain, Pain, Pain, Intractable

NCT04572776 2021-11-09

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Sorrento Therapeutics, Inc.

Phase 3 Withdrawn

Cancer Pain, Pain, Pain, Intractable

NCT03226574 2020-10-20

Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain

Sorrento Therapeutics, Inc.

Phase 1 Completed
17 enrolled

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡